Luca Gattinoni Curriculum Vitae 2013 - Center for Cancer Research ...

Business Address
National Cancer Institute
CRC, Room 3E-3150
10 Center Drive
Bethesda, MD 20892, US
Tel. +1-301-451-6914
Fax. +1-301-480-4354
e-mail gattinol@mail.nih.gov
Place and Date of birth
May 25, 1973 Milan
Citizenship
Italian
Luca Gattinoni, MD
Curriculum Vitae
Education
1999 Member of Italian College of Physicians
1998 M.D. School of Medicine and Surgery, "Università degli Studi di Milano” Milan: summa cum laude
1992 GCE A-level, Liceo Classico G. Carducci, Milan
Board certification
2003 EEC Board Certification in Medical Oncology,"Università degli Studi di Milano” Milan: summa cum laude
Employment
03/2013-present: Tenure-track investigator, Experimental Transplantation and Immunology Branch, National Cancer
Institute, Bethesda (USA) working to devolop new T-cell based immunotherapies for the treatment of patients with
cancer using murine models.
07/2008-03/2013: Staff Scientist, Surgery Branch, National Cancer Institute, Bethesda (USA) 11/2006-07/2008: Research
Fellow, Surgery Branch, National Cancer Institute, Bethesda (USA).
04/2003-11/2006: Visiting fellow, Surgery Branch, National Cancer Institute, Bethesda (USA).
11/1998-11/2003: Resident in Medical Oncology, Medical Oncology B Unit, Istituto Nazionale dei Tumori, Milan,
participating in clinical trials regarding patients affected by melanoma, and breast cancer. Residency thesis title:
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus
subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
11/1998-04/2003: Part-time collaboration at Cancer Immunotherapy and Gene Therapy Program of Istituto Scientifico
H.S.Raffaele of Milan doing research to identify new tumor associated antigens expressed by renal cell cancer.
08/1998-01/1999: Medical traineeship at Istituto Scientifico H.S.Raffaele, Milan.
1996-1998 Student at the Cancer Immunotherapy and Gene Therapy Laboratory of Istituto Scientifico H.S.Raffaele,
Milan; degree thesis title: Induction of cytotoxic T lymphocytes specific for peptides encoded by DAM gene family:
implications for tumor specific immunotherapy
Military Service
04/2001-03/2002 Military service as Health Officer (second-lieutenant) at 2°RGT of Corps of Engineers , Piacenza
01/2001-03/2001 136° Course AUC (Allievi Ufficiali di Complemento) of Army Medical Corps, Scuola SANIVET Rome-
Cecchignola
Awards and honors
December 2012: Earl Stadtman investigator, NIH
September 2012: The Wilson S. Stone Memorial Award, MD Anderson Cancer Center, University of Texas
October 2011: CHI–FOCIS Bedside to Bench & Back Lecture Series Achievement Award
October 2010: iSBTc Team Science Award (International Society for Biological Therapy of cancer 25 th Annual Meeting
2010, Washington DC)
April 2006: NIH Cytokine Interest Group Award: Best cytokine publication 2005
February 2006: NIH Exceptional Performance Award, Bethesda MD
November 2004: Presidential Award (International Society for Biological Therapy of cancer 19 th Annual Meeting 2004,
San Francisco CA)

October 2004: NIH Fellows Award for Research Excellence (FARE) 2005, Bethesda MD
Grants
July 2010: NIH CRM FY10 Award: Reprogramming tumor-specific T cells using iPS for cancer immunotherapy; $200,000
(Co-investigator)
December 2011: NIH CRM FY 12 Award: Hastening bench to bedside translation of regenerative medicine using lineage
reprogramming of tumor-specific T cells in patients with metastatic cancer; $125,000 (Co-investigator)
January 2013: 2013 NCI Director’s Intramural Innovation Award: Enhancing the efficacy of adoptive T cell-based
therapies in lymphoreplete hosts using miR-155 engineered tumor-specific CD8 + T cells; $50,000 (Principal Investigator)
Patents
April 2012: Exposing T cells to Fas Ligand (FasL)-Fas Receptor (FasR) Antagonists Withholds Differentiation and
Increases Expansion Making T cells More Suitable for Use in Cancer Immunotherapy. U.S. Patent Application No.
61/623,733
September 2012: Methods of producing T memory stem cell populations. International Patent Application No.
PCT/US2012/053947
October 2012: Compositions and methods for enhancing cancer immunotherapy. U.S. Provisional Patent
Application No. 61/716,653
Societies
2007-present: Member of the Global Cancer Control Community of the UICC (Union for International Cancer Control)
2006-present: Life member of the UICC (Union for International Cancer Control) Fellows
2003-2005: American Society of Clinical Oncology
Editorial
2013-present: member of the Editorial Board, Cancer Immunology Research
2011-present: member of the Editorial Board, Frontiers Immunology–Frontiers in Tumor Immunity section
2011-present: member of the Editorial Board, Clinical and Developmental Immunology
2009-present: member of the Editorial Board, Experimental and Therapeutic Medicine
Ad hoc Reviewer for Nature Immunology, Blood, Cancer Research, Journal of Leukocyte Biology, Plos One, Journal
of Immunotherapy, Cancer Immunology Immunotherapy, Journal of Translational Medicine, Journal of Investigative
Dermatology and Immunotherapy
Mentoring
2008-present: Yun Ji, Research fellow
2008-2013: Madusudhanan Sukumar, Postdoctoral Fellow
2005-2006: Anju Ranganathan, HHMI-NIH Research Scholar
Languages
Italian, English and French

Peer reviewed Publications
1. Dudda JC, Salaun B, Ji Y; Palmer DC, Monnot GC; Merck E, Boudousquie C, Utzschneider D, Escobar TM, Perret R,
Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L*, Romero PJ*. MicroRNA-155 is
required for effector CD8 + T cell responses to virus infection and cancer. Immunity 2013, in press * equally contributed
2. Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Modulating the differentiation status of
ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 2013, in press.
3. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick
E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M. Superior T Memory Stem Cell Persistence Supports
Long-Lived T-cell Memory. J Clin Invest 2013, 123:594–599
4. Gattinoni L and Restifo NP. Moving T memory stem cells to the clinic. Blood 2013, 121:567–568
5. Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M. Identification, isolation and in vitro
expansion of human and nonhuman primate T stem cell-memory cells. Nature Protoc 2013, 8:33–42
6. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: Which T cell populations mediate highly effective
adoptive immunotherapy? J Immunother 2012, 35:651–660.
7. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate anti-tumour cell. Nature Rev Cancer
2012, 12: 671–684
8. Klebanoff CA, Gattinoni L. Stubborn Tregs limit T cell therapy. Blood 2012, 120:2352–2354
9. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM,
Miller JS, Mostoslavsky G, Powell DJ Jr, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ. New directions in cellular
therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012, 10:48
10. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ,
Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner
RL, Gattinoni L, Restifo NP. Th17-derived memory cells are long-lived and retain a stem cell-like molecular signature.
Immunity 2011, 35:1–14
11. Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump
DS, Marincola FM, Restifo NP, Gattinoni L. Repression of the DNA-binding inhibitor Id3 by Blimp1 limits the formation of
memory CD8+ T cells. Nature Immunol 2011, 12:1230–1237
12. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick, E, Yu Z, Carpenito C, Wang E, Douek DC,
Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human T cell memory subset with stem cell-like properties.
Nature Med 2011, 17:1290–1297
13. Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, Gattinoni L, Restifo NP, Huang S, Zhao K. Regulation of
nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome res 2011,
21:1650–1658
14. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE,
Rosenberg SA, Restifo NP. Determinants of successful CD8 + T cell adoptive immunotherapy for large established tumors
in mice. Clin Cancer Res 2011, 17:5343–5352
15. Kerkar SP, Sanchez-Perez L, Yang S, Borman Z, Muranski P, Ji, Y, Chinnasamy D, Kaiser ADM, Hinrichs CS, Klebanoff
CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP. Genetic engineering of murine CD8 + and CD4 + T cells
for preclinical adoptive immunotherapy studies. J Immunother 2011, 34:343–352
16. Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA In vitro generated anti-tumor T
lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother 2011,
60:739–749
17. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z,. Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S,
Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP. Human effector CD8 + T cells
derived from naïve rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011,
117:808–814
18. Gattinoni L, Ji Y, Restifo NP. Wnt/β-catenin signaling in T cell immunity and cancer immunotherapy. Clin Cancer Res
2010, 16:4695–4701
19. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan
RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP. Tumor-specific CD8 + T cells expressing IL-12 eradicate
established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725–6734
20. Gattinoni L, Ji Y, Restifo, NP. Reply to β-catenin does not regulate memory T cell phenotype Nature Med. 2010, 16:
514–515
21. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S,
van den Broek M, Radbruch A, Lévy F, Lambert P, Siegrist C, Restifo NP, Löhning M, Ochsenbein AF, Nabel J, Pinschewer
DD. Development of replication-defective lymphocytic choriomeningitis virus vectors for induction of potent CD8 + T cell
immunity. Nature Med 2010, 16:339–345
22. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased
intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J
Immunother 2010; 33:1–7
23. Gattinoni L, Klebanoff CA, Restifo NP. Pharmacologic Induction of CD8 + T cell memory: Better Living through
chemestry. Science Transl Med 2009, 1:ps12

24. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer
DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP. Adoptively transferred effector cells derived from
naive rather than central memory CD8 + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009,
106:17469–17474
25. Klebanoff CA, Yu Z, Hwang L, Palmer DC, Gattinoni L, Restifo NP. Programming tumor-reactive effector memory
CD8 + T cells in vitro obviates the requirement for in vivo vaccination. Blood 2009, 114:1776–1783
26. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Church L, Paulos CM,
Muranski P, Restifo NP. Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells.
Nature Med 2009, 15:808–813
27. Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA,
Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across
major histocompatibility barriers. Blood 2008, 112:4746–4754
28. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann K, Feigenbaum L, Chan CC, Restifo NP. Tumor-specific Th17-polarized
cells eradicate large established melanoma. Blood 2008, 112:362–373
29. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE,
Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a
melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA 2008,
105:8061–8066
30. Hinrichs CS, Spolsky R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ,
Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8 + T cells for adoptive immunotherapy. Blood
2008 , 111:5326–5333
31. Abad JD, Wrzesinski C, Overwijk WW, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC,
Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-Cell Receptor Gene Therapy of Established Tumors
in a Murine Melanoma Model. J Immunother 2008, 31:1–6
32. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z,
Antony, PA, Gattinoni L , Rosenberg SA, Restifo, NP. Toll-like receptors in Tumor Immunotherapy. Clin Cancer Res 2007,
13:5280–5289
33. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni
L, Antony PA, Rosenberg SA, Restifo, NP. Microbial translocation augments the function of adoptively transferred
self/tumor-specific CD8 + T cells via Toll-Like Receptor 4. J Clin Invest 2007, 117:2197–2204
34. Lionello L, Mangia P, Gattinoni L, Pende D, Cipponi A, Sensi M, Rigatti P, Traversari C. CD8 + T lymphocytes isolated
from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. Cancer
Immunol Immunother 2007, 56:1065–1076
35. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L , Restifo NP, Rosenberg SA, Morgan RA. Extra-thymic
generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer Res, 2007, 67:2425–242932.
36. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA and Restifo NP. Hematopoietic stem
cells promote the expansion and function of adoptively transferred antitumor CD8 + T cells. J Clin Invest 2007, 117: 492–
501
37. Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo
NP. CTLA-4 dysregulation of self/tumor-reactive CD8 + T cell function is CD4 + T cell-dependent. Blood 2006, 108:3818–
3823
38. Klebanoff CA*, Gattinoni L*, Restifo NP. CD8 + T cell memory in tumor immunology and immunotherapy. Immunol
rev 2006, 211:214–224 * equally contributed
39. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8 + T cells for effective immunotherapy. Curr Opin Immunol,
2006, 18:363–370
40. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success.
Nature Rev Immunol 2006, 6:383–393
41. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-Efficiency
Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Mol Ther 2006, 13:151–159
42. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann
DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the
efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med 2005, 202:907–912
43. Klebanoff CA*, Gattinoni L*, Torabi-Parizi P, Kerstann K, Cardones AR, Finkselstein SE, Palmer DC, Antony PA, Hwang
ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8 + T cells confer superior
antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005, 102:9571–9576 * equally
contributed
44. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA,
Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively
transferred CD8 + T cells. J Clin Invest. 2005, 115:1616–1626

45. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre, S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N,
Buzzoni R. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older
women. J Clin Oncol 2005, 23: 2155–2161
46. Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA,
Gattinoni L, Goldstein AL, Yang JC Restifo NP Vaccine-stimulated, Adoptively Transferred CD8 + T Cells Traffic
Indiscriminately And Ubiquitously While Mediating Specific Tumor Destruction. J Immunol 2004, 173:7209–7216
47. Finkelstein SE, Heimann DM, Klebanoff AC, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ,
Surman DR , Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP: Bedside to bench and back again: How animal models are
guiding the development of new immunotherapies for cancer. J Leukoc Biol 2004, 76:333–337
48. Melloni G, Ferreri AJM, Russo V, Gattinoni L, Arrigoni L, Ceresoli GL, Zanini P, Traversari C. Prognostic significance of
cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 2004, 12:145–151
49. Klebanoff AC, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Palmer DC,
Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP: IL-15 enhances the in vivo anti-tumor activity of tumor-reactive CD8 +
T cells. Proc Natl Acad Sci USA 2004, 101: 1969–1974
50. Del Vecchio M, Gattinoni L, Lozza L, Bajetta E. Regionally Advanced Nasal Cavity Melanoma. J Clin Oncol 2004, 22:
745–746
51. Gattinoni L, Alù M, Ferrari L, Nova P, Del Vecchio M, Procopio G, Laudani A, Agostara B, Bajetta E. Renal cancer
treatment: a review of the literature. Tumori 2003, 89: 476–484
52. Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E, Bombardieri E.
Could Exemestane affect on Insuline-like growth factors, interleukin 6 and bone metabolism in postmenopausal
advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003, 22:
1081–1089
53. Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I, Gattinoni L, Catena L, Vitali M, Celio L, Seregni E,
Bombardieri E, Bajetta E. Short-term effects of Anastrozole treatment on Insuline-Like Growth Factor System in
postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 2002, 80: 411–418
54. Fleischhauer K, Gattinoni L, Lietti G, Zino E, Bordignon C, Traversari C. Identification of Tumor Antigen Specific
Cytotoxic T Lymphocytes cross-recognizing allogenic major histocompatibility class I molecules. Tissue Antigens 2000,
56: 19–29
55. Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert P, Bordignon C,Traversari C. The
DAM-Gene Family encodes a New Group of Tumor-specific Antigens recognised by Human Leukocyte Antigen A2-
Restricted Cytotoxic T Lymphocytes. Cancer Res 1998, 58: 2969–2972
Invited Lectures
1. T memory stem cells sustain the long-term maintenance of T cell memory. Keystone Symposia: Emerging Topics in
Immune System Plasticity, Santa Fe, NM, US, January 15-20, 2013
2. Paths to stemness: building the ultimate antitumour T cell. JNI Oncology Lectures, Erasmus MC, Rotterdam, The
Netherlands, October 24, 2012
3. A human memory T cell subset with stem cell-like properties. CHI symposium: The human immune system after
perturbation and in disease, Bethesda, MD, US, October 9, 2012
4. Fighting fire with fire: Eradicating tumors with stem cell-like T cells. Immunology and Inflammation in Cancer. Wilson
S. Stone Memorial Award Lecture. MD Anderson Cancer Center, Houston, TX, US, September 21-22, 2012
5. Programming and reprogramming T cell fate for therapeutic use. NCMLS seminar, Nijmegen, The Netherlands, June
11, 2012
6. Fighting fire with fire: Eradicating tumors with stem cell-like T cells. Dutch Tumor Immunology Meeting, Keynote
Lecture, Breukelen, The Netherlands, June 7-8, 2012
7. Programming and reprogramming T cell fate for therapeutic use. Experimental Transplantation Immunology Branch
seminar, Bethesda, MD, US, March 21, 2012
8. Identification of self-renewing, multipotent CD8 + memory stem cells in mice and humans. Summit on Cell Therapy for
Cancer, Bethesda, MD, US, November 1-2, 2011
9. The self-renewing, multipotent CD8 + memory stem cells. BB&B lecture series FOCIS/CHI, NIH, Bethesda, MD, US,
October 19, 2011
10. The self-renewing, multipotent CD8 + memory stem cells. 44th SLB (Society for Leukocyte Biology) Annual Meeting,
Kansas City, MO, September 22-24, 2011
11. An early human memory T cell subset with stem cell-like properties. Keystone Symposia: Immunologic Memory,
Persisting Microbes and Chronic Disease, Banff, Alberta, Canada, February 6-11, 2011
12. Adoptive immunotherapy in immune-depleted melanoma patients. 5 th Meeting on Combined Biotherapy of Cancer
of the Program 2 Alleanza contro il cancro, Milan, Italy, April 9 -10, 2010
13. Basic principles guiding the development of new adoptive immunotherapies. University of Lausanne, Epalinges,
Switzerland, December 16, 2009
14. Basic principles guiding the development of new adoptive immunotherapies. EXTERNAL SEMMinars, European
School of Molecular Medicine, Milan, Italy , December 14, 2009
15. Activation of Wnt Signaling with Inhibitors of Gsk-3 Promotes the Generation of highly effective CD8 + Memory
Stem Cells for immunotherapy. WNT 2009 Meeting, Washington, DC, US, June 11-14, 2009

16. Basic principles guiding the development of new adoptive immunotherapies. Cellular Therapy of Cancer
Symposium, Milan, Italy , March 27-29, 2009
17. Activation of Wnt Signaling with Inhibitors of Gsk-3 Promotes the Generation of CD8 + Memory Stem Cells. NIH
Immunology Interest Group Seminar Series, Bethesda, MD, US, February 18, 2009
18. The Adoptive transfer of CD8 + memory stem cells. Univeristy of Miami, Miami, FL May 19, 2008
19. The Adoptive transfer of CD8 + memory stem cells. 14th ISCT (International Society for Cellular Therapy) Annual
Meeting, Miami, FL, US, May 17-20, 2008
20. CD8 + T cells for adoptive therapy of cancer. Cancer Biology and Immunology Day Symposium (Royal Society of
Medicine), London UK, May 12, 2008
21. The Adoptive transfer of CD8 + memory stem cells. NERD (Novel Experimental Research Developments) series,
Center for Human Immunology, NIH, Bethesda, MD, US, January 25, 2008
22. The importance of T cell differentiation in TCR gene therapy. Cellular Therapy of Cancer Symposium, Manchester,
UK, December 2-3, 2006
23. Terapia con linfociti citotossici. VIII AIOM (Associazione Italiana di Oncologia Medica) National Conference, Milan,
Italy, November 19-21, 2006
24. The basic science behind adoptive cell transfer therapies. Istituto Nazionale Tumori, Milan, October 10, 2005
25. The basic science behind adoptive cell transfer therapies. Vita-Salute San Raffaele University, Milan, October 10,
2005
26. Lymphodepleting therapy and TIL. 2nd ATST (Allogeneic Transplantation in Solid Tumors) Meeting, Stresa, Italy,
October 7-8, 2005
27. Acquisition of terminal effector function in vitro impairs in vivo anti-tumor efficacy. ISBTc (International Society for
Biological Therapy of Cancer) 19 th Annual Meeting 2004, San Francisco CA November 4-7, 2004
28. Acquisition of terminal effector function in vitro impairs in vivo anti-tumor efficacy of adoptively transferred
lymphocytes. 2004 NIH Immunology Retreat, Airlie VA, October 13- 15, 2004
29. When good T cells go bad: acquisition of terminal effector function in vitro impairs in vivo anti-tumor efficacy.
Experimental Biology 2004, Washington DC April 17-21, 2004
30. L’Oncologia Medica della terza eta’: Dimensione epidemiologica. XII Riunione Nazionale Gruppo I.T.M.O. (Italian
Trials in Medical Oncology), Milan, Italy, February 7, 2003
31. Ormonoterapia sequenziale con Exemestane in fase adiuvante. IX Riunione Nazionale Gruppo I.T.M.O. (Italian
Trials in Medical Oncology), Milan, Italy, November 27, 2000